FDA’s approval of Otarmeni, the first gene therapy for hereditary deafness
In a lab room, a toddler, deaf from birth, sits while a tone plays. There’s no reaction. His face does...
FDAs
Capricor Therapeutics: Buying Opportunity Following FDA’s CRL (CAPR)
This article was written byFollowBackground: Physician involved in clinical research. Investment style: Clinical-stage biotech stocks, long only, both long-term ideas and event-driven...
